Latest News and Press Releases

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis’ in radioligand therapy to explore the potential for novel targeted therapies for cancerNovartis...

Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency...

Program overview and study design for MP0317 to be presented at ESMO Immuno-OncologyPreclinical data supporting novel mechanism of AML candidate MP0533 to be presented at ASHOncology R&D Day to...

First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical...

Research collaboration with leading acute myeloid leukemia (AML) experts, Professor Ochsenbein and Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital,...

Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concernTesting on the full Omicron variant has initiated, with...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized...

Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technologyPreclinical data support potential to deliver tumor-localized immune...